Moderna and Merck unveil mRNA cancer vaccine that cuts melanoma recurrence

Moderna and Merck have presented late-stage trial results for their mRNA-based cancer vaccine, Intismeran, targeting melanoma. The data show the vaccine reduces both disease recurrence and spread. The results mark a significant advance in the use of mRNA technology in cancer treatment.